6533b7d4fe1ef96bd1261ef3
RESEARCH PRODUCT
An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.
Raul D. SantosAda CuevasAndrey V. SusekovS. LaletokgözogluScott M. GrundyMichael H. DavidsonGerald F. WattsD. John BetteridgeDong ZhaoY. Antero KesäniemiShaukat SadikotHidenori AraiJacques GenestRafael CarmenaThomas P. BersotPhilip J. BarterRody G. Sysubject
Gerontologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismAlternative medicineMEDLINEPharmacologychemistry.chemical_compoundPharmacotherapyRisk FactorsEnvironmental healthInternal MedicinemedicineHumansSocieties MedicalDyslipidemiasMetabolic SyndromeNutrition and DieteticsExecutive summaryCholesterolLife stylebusiness.industryAnticholesteremic AgentsCholesterol LDLmedicine.diseaseDietchemistryCardiovascular DiseasesPosition paperlipids (amino acids peptides and proteins)Lifetime riskPopulation RiskMetabolic syndromeRisk assessmentCardiology and Cardiovascular MedicinebusinessDyslipidemiadescription
An international panel of the International Atherosclerosis Society has developed a new set of recommendations for management of dyslipidemia. The panel identifies non-high density lipoprotein cholesterol (non-HDL-C) as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for higher risk subjects. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-02-01 | Journal of clinical lipidology |